TY - JOUR
T1 - The Association of β2-Microglobulin and Fibroblast Growth Factor 23 with Major Adverse Cardiac Event in Acute Coronary Syndrome Patients with Chronic Kidney Disease
AU - Ginanjar, Eka
AU - Alwi, Idrus
AU - Lydia, Aida
AU - Immanuel, Suzanna
AU - Indrajaya, Taufik
AU - Harimurti, Kuntjoro
AU - Yamin, Muhammad
N1 - Funding Information:
This study was sponsored by Universitas Indonesia through the PITTA UI (Hibah Publikasi Internasional Terindeks untuk Tugas Akhir Mahasiswa Univeristas Indonesia) 2018 and TADOK UI (Hibah Tugas Akhir Mahasiswa Doktor Universitas Indonesia) 2018 programs.
Publisher Copyright:
© 2021, Indonesian Society of Internal Medicine. All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - BACKGROUND: chronic kidney disease (CKD) increases the severity and risk of mortality in acute coronary syndrome (ACS) patients. The role of β2-M as a filtration and inflammation marker and FGF23 as a CKD-MBD process marker might be significant in the pathophysiology in ACS with CKD patients. This study aims to determine the association of β2-M and FGF23 with major adverse cardiac event (MACE) in ACS patients with CKD. METHODS: we used cross sectional and retrospective cohort analysis for MACE. We collected ACS patients with CKD consecutively from January until October 2018 at Dr. Cipto Mangunkusumo General Hospital. Data were analyzed using logistic regression and Cox's Proportional Hazard Regression. RESULTS: a total of 117 patients were selected according to the study criteria. In bivariate analysis, β2-M, FGF23, and stage of CKD had significant association with MACE (p = 0.014, p = 0.026, p = 0.014, respectively). In multivariate analysis, β2-M - but not FGF 23- was significantly associated with MACE (adjusted HR 2.16; CI95% 1.15-4.05; p = 0.017). CONCLUSION: β2-M was significantly associated with MACE, while FGF23 was not so. This finding supports the role of inflammation in cardiovascular outcomes in ACS with CKD patient through acute on chronic effect.
AB - BACKGROUND: chronic kidney disease (CKD) increases the severity and risk of mortality in acute coronary syndrome (ACS) patients. The role of β2-M as a filtration and inflammation marker and FGF23 as a CKD-MBD process marker might be significant in the pathophysiology in ACS with CKD patients. This study aims to determine the association of β2-M and FGF23 with major adverse cardiac event (MACE) in ACS patients with CKD. METHODS: we used cross sectional and retrospective cohort analysis for MACE. We collected ACS patients with CKD consecutively from January until October 2018 at Dr. Cipto Mangunkusumo General Hospital. Data were analyzed using logistic regression and Cox's Proportional Hazard Regression. RESULTS: a total of 117 patients were selected according to the study criteria. In bivariate analysis, β2-M, FGF23, and stage of CKD had significant association with MACE (p = 0.014, p = 0.026, p = 0.014, respectively). In multivariate analysis, β2-M - but not FGF 23- was significantly associated with MACE (adjusted HR 2.16; CI95% 1.15-4.05; p = 0.017). CONCLUSION: β2-M was significantly associated with MACE, while FGF23 was not so. This finding supports the role of inflammation in cardiovascular outcomes in ACS with CKD patient through acute on chronic effect.
KW - Acute Coronary Syndrome
KW - Beta2-Microglobulin
KW - Fibrioblast Growth Factor 23
KW - Major Adverse Cardiac Event
UR - http://www.scopus.com/inward/record.url?scp=85103921128&partnerID=8YFLogxK
M3 - Article
C2 - 33818401
AN - SCOPUS:85103921128
SN - 0125-9326
VL - 53
SP - 5
EP - 12
JO - Acta medica Indonesiana
JF - Acta medica Indonesiana
IS - 1
ER -